Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nilvadipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Study shows Nilvadipine slows early-stage Alzheimer’s disease
    Study shows Nilvadipine slows early-stage Alzheimer’s disease

    10 Mar 2020

    // CLINICAL TRIAL

    https://www.clinicaltrialsarena.com/news/nilvadipine-slowdowns-early-stage-alzheimers/

    CLINICAL TRIAL
    10 Mar 2020
    Share Share
    Study shows Nilvadipine slows early-stage Alzheimer’s disease
    Study shows Nilvadipine slows early-stage Alzheimer’s disease

    09 Mar 2020

    // REUTERS

    https://www.clinicaltrialsarena.com/news/nilvadipine-slowdowns-early-stage-alzheimers/

    REUTERS
    09 Mar 2020
    Share Share
    New Roskamp Institute Clinical Research Shows Promise of Drug to Slow
    New Roskamp Institute Clinical Research Shows Promise of Drug to Slow

    06 Mar 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-roskamp-institute-clinical-research-shows-promise-of-drug-yo-slow-early-stage-alzheimers-disease-301019187.html

    PR NEWSWIRE
    06 Mar 2020
    Share Share